CJC-1295 Ipamorelin for Sale: How to Read a Listing (2026)

The nine things a listing must say

Which CJC-1295. DAC or no DAC (Mod GRF 1-29). A blend should say Mod GRF 1-29 or "no DAC".
The mass of each component. "10 mg" is not enough; "5 mg + 5 mg" is.
A certificate of analysis for the lot, with two HPLC peaks, two purity figures and two mass confirmations.
The testing laboratory's name and a report number that can be checked on the laboratory's own site.
The lot number, printed on the vial and matching the certificate.
Where the vial ships from, and in how many days.
The price per vial, from which the price per milligram follows.
Storage: lyophilized, sealed, cold, protected from light.
The research-use-only statement, stated plainly, not hidden.

Everything below is an expansion of one of those nine lines.

Which CJC-1295: the first question, and the one most listings dodge

"CJC-1295" names two molecules. The one ConjuChem patented and tested in humans carries a maleimide-lysine tail that binds serum albumin after injection and gives it a half-life of 5.8 to 8.1 days [Jetté et al., 2005] [Teichman et al., 2006]. The one that goes into blends is the same peptide without the tail, called Mod GRF 1-29, cleared in minutes. Ipamorelin lasts about two hours [Gobburu et al., 1999].

A vial that pairs the week-long molecule with the two-hour one is a product whose two halves do not work on the same clock, which is why every serious blend uses the no-DAC form and why a listing that does not say which form it contains has failed the first test. The chemistry and the consequences are in CJC-1295 DAC versus no DAC.

Reading the certificate: two peaks, two masses

A two-peptide vial has to be tested as two peptides. On reverse-phase HPLC the pentapeptide elutes early and the 29-residue analogue late, so a genuine chromatogram shows two separate main peaks, and a laboratory that does its job reports a purity for each. On mass spectrometry the certificate must show both expected masses: 711.9 for ipamorelin, the mass Raun and colleagues published in 1998 [Raun et al., 1998], and about 3,368 for Mod GRF 1-29, computed from the sequence in the 2005 ConjuChem paper [Jetté et al., 2005]. A mass near 3,647 in a vial sold as "no DAC" means the DAC form was used. A single averaged "99 %" for the vial hides which component is under specification.

Beyond the numbers, a certificate is only as good as its provenance: the laboratory's name, a report number that resolves on the laboratory's own website, the date, the lot number identical to the one on the vial, and ideally a photograph of the tested vial wearing the supplier's label. A certificate that lacks the lot number describes a compound, not the vial in your hand.

The price, per milligram

Price only means something per milligram and per certificate. The supplier page this site links to lists the 10 mg blend (5 mg of Mod GRF 1-29 plus 5 mg of ipamorelin) at 95 US dollars, which is 9.50 dollars per milligram of total peptide, with the lot certificate published on the page, tracked shipping, and volume discounts from two vials.

Buying the two components as separate 5 mg vials from the same catalogue costs more, because two vials mean two fills, two labels and two laboratory tests. The general rule follows: for the same stated mass, a listing far below the going per-milligram price is usually saving on the thing that is invisible, the testing.

Swipe sideways to see the whole table.

What is listed	Total peptide	Price	Per mg	Certificates
Blend vial, 5 mg + 5 mg	10 mg	$95	$9.50	1 lot COA, two masses
Two separate 5 mg vials	10 mg	more than the blend	higher	2 lot COAs
"10 mg blend", no COA, no lab named	unknown	often lower	meaningless	0

Origin and shipping

Lyophilized peptides tolerate a few days at ambient temperature, so the concern with origin is less the cold chain than the customs desk and the time. A vial shipped from domestic stock in the United States arrives in days with tracking; a vial routed from abroad can spend weeks in transit and may not arrive at all. A listing should therefore say where the vial physically ships from, not only where the company is registered. For European readers the same logic points to stock held inside the European Union.

The legal frame

Neither CJC-1295 nor ipamorelin is an approved medicine anywhere. ConjuChem's phase 2 trial ended in 2006 and Helsinn's ipamorelin programme ended in 2014 [Beck et al., 2014]. In the United States the pair reaches buyers as a research chemical, sold to laboratories and qualified researchers for in-vitro research and labelled "not for human consumption"; that label is the legal frame of the transaction, and a listing that omits it, or that describes effects on people, has stepped outside it.

On September 29, 2023 the FDA placed ipamorelin acetate in category 2 of its list of bulk substances for compounding that "may present significant safety risks", citing possible immunogenicity [U.S., 2023], which closed the compounding-pharmacy route most clinics had used. In sport, both peptides are named in class S2 of the WADA Prohibited List and are banned at all times [World, 2026]; an athlete subject to testing should read no further than that sentence.

Red flags, in order of how often they appear

The listing does not say DAC or no DAC.
One purity number for a two-peptide vial.
No laboratory named, or a certificate with no lot number and no report number.
A mass near 3,647 on a certificate for a blend.
The page describes outcomes in people, quotes a protocol, or shows before-and-after photographs; those are the words of a clinic, not a reagent supplier.
Reviews that describe personal results: a research-use listing cannot honestly carry them.
A price per milligram far below the market for the same stated mass.
No shipping origin stated.

Why this site links to one supplier page

This site sells nothing, runs no advertising and takes no commission. It links to one product page, the CJC-1295 / ipamorelin blend at OXpeptides, because that page meets the nine points above as this site reads them: the form is named, the two masses are stated, the lot certificate is published, the vial ships tracked from domestic stock in the United States or the European Union, and the research-use statement is printed rather than hidden. If that changes, the link will. Corrections go to editor@cjc-1295-ipamorelin.com, as described in the editorial policy.

Sources

Each DOI below returned HTTP 200 on api.crossref.org and each NCT number on clinicaltrials.gov when this page was last updated. Nothing is cited from memory.

Jetté L, Léger R, Thibaudeau K, Benquet C, Robitaille M, Pellerin I, Paradis V, van Wyk P, Pham K, Bridon DP (2005). Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology 146(7):3052-3058. doi:10.1210/en.2004-1286CrossRef 200
The ConjuChem paper that names CJC-1295: a tetrasubstituted hGRF(1-29) with a maleimidopropionamide lysine at the C-terminus that binds Cys34 of serum albumin. In rats, 4-fold GH area under the curve versus hGRF(1-29) over 2 hours, detectable in plasma beyond 72 hours.1
Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH (1998). Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology 139(5):552-561. doi:10.1530/eje.0.1390552CrossRef 200
The Novo Nordisk paper that describes ipamorelin (Aib-His-D-2-Nal-D-Phe-Lys-NH2). EC50 1.3 nmol/l in rat pituitary cells, ED50 2.3 nmol/kg in swine, no ACTH or cortisol release at more than 200 times the GH ED50, no effect on FSH, LH, PRL or TSH.2
Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology & Metabolism 91(3):799-805. doi:10.1210/jc.2005-1536CrossRef 200
Two randomized, placebo-controlled, double-blind ascending-dose trials (28 and 49 days) in healthy adults aged 21 to 61. Four ascending single doses in the first study (30 and 60 µg/kg named as the best tolerated); two or three weekly or biweekly doses in the second. Half-life 5.8 to 8.1 days.3
Gobburu JV, Agersø H, Jusko WJ, Ynddal L (1999). Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharmaceutical Research 16(9):1412-1416. doi:10.1023/A:1018955126402CrossRef 200
Five intravenous infusion rates (4.21 to 140.45 nmol/kg over 15 minutes) in eight healthy men per dose level. Terminal half-life 2 hours, clearance 0.078 l/h/kg, one GH episode peaking at 0.67 hours, SC50 214 nmol/l.4
U.S. Food and Drug Administration (2023). Certain bulk drug substances for use in compounding that may present significant safety risks. FDA, Human Drug Compounding. www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-s…
Ipamorelin acetate placed in category 2 on September 29, 2023, with the wording that compounded drugs containing it may pose a risk for immunogenicity for certain routes of administration. The CJC-1295 nomination appears on the same page among the nominations later withdrawn.5
World Anti-Doping Agency (2026). The Prohibited List, class S2 (peptide hormones, growth factors, related substances and mimetics). WADA. www.wada-ama.org/en/prohibited-list…
GHRH analogues (CJC-1295, sermorelin, tesamorelin) and growth hormone secretagogues (ipamorelin and the GHRPs) are listed by name as prohibited at all times.6
Beck DE, Sweeney WB, McCarter MD, Ipamorelin 201 Study Group (2014). Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. International Journal of Colorectal Disease 29(12):1527-1534. doi:10.1007/s00384-014-2030-8CrossRef 200 NCT00672074CT.gov 200
Phase 2, multicentre, double-blind, placebo-controlled. 117 enrolled, 114 analysed. Intravenous 0.03 mg/kg twice daily for up to 7 days. Adverse events in 87.5 % (ipamorelin) versus 94.8 % (placebo). Median time to first tolerated meal 25.3 versus 32.6 hours, p = 0.15.7

Questions readers ask

Is it legal to buy CJC-1295 ipamorelin?

In the United States the pair is sold as a research chemical, labelled for research use only and not for human consumption; that is the frame the supplier and the buyer both operate in. Neither peptide is an approved drug, the FDA placed ipamorelin acetate in category 2 of its compounding list in September 2023, and both are prohibited in sport under WADA class S2. This site does not sell anything and does not give legal advice.

What should a CJC-1295 ipamorelin listing state?

Which CJC-1295 it contains (DAC or Mod GRF 1-29), the mass of each component, a certificate of analysis for the lot with two HPLC peaks and two masses (near 3,368 and 711.9), the name of the testing laboratory and a verifiable report number, the lot number printed on the vial, where the vial ships from, the price per vial and therefore per milligram, storage conditions, and a research-use-only statement.

What is a normal price for a CJC-1295 ipamorelin vial in 2026?

A 10 mg blend (5 mg + 5 mg) with a published per-lot certificate is listed at 95 US dollars at OXpeptides, which is 9.50 dollars per milligram; a pair of separate 5 mg vials costs more because it means two fills and two certificates. Listings far below that for the same mass usually save on the testing.

Why does a blend need two masses on the certificate?

Because equal mass is not the same as the right molecules. A 5 mg + 5 mg vial must show a mass near 3,368 for Mod GRF 1-29 (3,647 would mean the DAC form) and 711.9 for ipamorelin, each with its own purity figure. One averaged purity number hides which component is short.

Questions or corrections: editor@cjc-1295-ipamorelin.com. See the editorial policy.